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Background: Leigh syndrome is a mitochondrial cytopathy that presents as a
neurodegenerative disease with apparent manifestation in the central nervous system.
The aim of the present study was to describe its dominant neurological clinical features
and analyze data related to epilepsy in Leigh syndrome accompanied by a mitochondrial
DNA mutation.
Methods: Whole mitochondrial sequencing was performed on 125 patients clinically
suspected of Leigh syndrome. Among them, 25 patients were identified to have
mitochondrial DNA associated Leigh syndrome. Electroencephalography (EEG) findings,
semiology, brain imaging findings, and biochemical results, were evaluated. We also
compared brain magnetic resonance imaging findings and biochemical features in
patients with Leigh syndrome based on the presence of epilepsy.
Results: Clinical seizures were observed in 14 out of 25 enrolled patients (56%), with
focal seizures being the most common type (6/14, 42.8%). All patients were found to
have slow and disorganized background neural activity while eight exhibited epileptic
discharges on EEG. Mutations at base pairs 10,191 and 8,993 were revealed in a
relatively larger number of patients of Leigh syndrome with epilepsy. The presence
of gastrointestinal symptoms was significantly more frequent in the epilepsy group
(P = 0.042). Diffuse cerebral atrophy was significantly increased (P = 0.042) and cortex
signal abnormalities were also increased (P = 0.033) in the epilepsy group.
Conclusions: Patients with Leigh syndrome and mitochondrial DNA mutations had
a high proportion of central nervous system comorbidities, though the prevalence of
epilepsy in this population was not particularly high. Various types of seizure and EEG
findings are common in those with Leigh syndrome. Future imaging studies involving
more patients and proper mitochondrial DNA mutation analyses are needed to further
evaluate the natural course of Leigh syndrome with epilepsy.
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INTRODUCTION
Leigh syndrome is a mitochondrial disorder, the diagnosis of which is defined by three key
characteristics. First, symmetrical brain stem and/or basal ganglia dysfunction on imaging is
required. Patients must also exhibit delayed intellectual and motor development, and/or elevated
serum or cerebrospinal fluid (CSF) lactate levels on laboratory findings, indicating abnormal energy
metabolism (1).
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Mitochondrial disorders are associated with heterogenous
manifestations due to their involvement of multiple organs and
physiological systems, though most affect the central nervous
system (CNS) (2). Epilepsy is a typical phenotypic feature of
mitochondrial disorders that affect the CNS (3). However, the
prevalence of epilepsy is not equal among all patients with
mitochondrial disorders. For instance, these rates vary among
Leigh patients withWest syndrome or epilepsia partialis continua
(4–6), in whom the incidence of epilepsy is extremely low.
The present study aimed to describe the neurological
manifestations of Leigh syndrome and, more specifically, analyze
data related to epilepsy in Leigh syndrome confirmed by
identification of a positive mitochondrial DNA mutation.
MATERIALS AND METHODS
Patients and Enrollment Criteria
We performed a retrospective review of the medical records
including genetic and laboratory reports of 125 patients with
Leigh syndrome who had been treated at Gangnam Severance
Hospital. All of the patients had confirmed mitochondrial
disease, per the criteria described by Bernier et al. (7).
Additionally, patients had confirmed diagnoses of Leigh
syndrome (LS), as confirmed by Rahman et al. (8). These criteria
include a progressive neurodegenerative disease with motor
and intellectual developmental delays, signs and symptoms of
brainstem and/or basal ganglia dysfunction on neuroimaging,
and elevated serum or CSF fluid lactate levels. Whole
mitochondrial sequencing was carried out on 125 clinically
diagnosed with Leigh syndrome. Among them, 27 patients have
mitochondrial DNA mutations but we excluded two patients
whose mitochondrial DNA mutations were of unidentified
type. Twenty five patients were genetically confirmed to
have mitochondrial DNA-associated Leigh syndrome and were
included in the study.
Evaluation of Mitochondrial Disease and
Leigh Syndrome
Diagnostic evaluations of patients with LS were performed.
These included laboratory assessments of serum lactate levels and
neuroimaging. The severity of serum lactic acidosis was defined
as normal, mild (≧2-fold normal reference value), moderate (≧3-
fold normal reference value). The neuroimaging modality used
was brain MRI, while MR spectroscopy was used to identify a
lactate peak in degenerated lesions of the brain.
Histological reports from biopsies of skeletal muscle taken
from 23 patients were reviewed. Using light and/or electron
microscopy, the presence of megaconia or pleoconia, or ragged
red fibers were used as specific findings to indicate mitochondrial
disease, while a preponderance of atrophic type I fibers were
defined as non-specific findings (7). As mitochondrial chain
complex (MRC) defects are defined as those below 20% of control
levels (9), we also set our reduction of residual enzyme activity
more strictly to <10% of controls. DNA from all patients were
assessed for mitochondrial DNA (mtDNA) mutations based on a
molecular sequencing analysis.
Epilepsy Related Analysis
Factors related to epilepsy, including seizure semiology and
the diagnostic evaluation tool developed by the International
League Against Epilepsy (ILAE) (10) classification as well as
EEG findings. Additional assessments of participant treatment
responses were based on numbers of anti-epileptic drugs and
seizure frequency.
Subgrouping and Statistical Analyses
Patients were divided into two groups based on their epilepsy
status. All analyses were performed using SPSS version 21.0 (IBM
Corp., Armonk, NY, USA). Descriptive statistics include medians
and ranges. Chi-squared distribution, the Mann-WhitneyU-test,
and the Pearson exact test were used to evaluate differences
between groups. A P < 0.05 was considered to indicate
statistical significance.
RESULTS
Clinical Characteristics
In total, 25 patients were enrolled in the present study, including
10 males and 15 females. A family history of mitochondrial
disease was noted in 4 of the 25 patients. The most common
first onset symptom was developmental delay (40.0%), followed
by seizures (12.0%). The mean age of first symptom onset was
approximately 1 year (range: 0.15–9.88 years) and all patients
were diagnosed within 9 years of first symptom onset. The
mean duration of follow-up in our institute was over 5 years.
All patients were involved in neuromuscular system treatment
(100%), while over half underwent ophthalmic treatment.
Developmental delays were evident alongside neuromuscular
symptoms in 68.0% of patients, while seizures were evident in
32.0% (Table 1).
Neuroimaging and Diagnostic Evaluation
of Leigh Syndrome
Increased signal intensity in the basal ganglia (92.0%) and
brain stem (76.0%) on MRI were both observed, with over
a half (84%) of patients exhibiting a lactate peak on plasma
MR spectroscopy. An additional 20 patients exhibited mildly
increased serum lactate levels. Electron microscopic changes
were identified, including pleoconia (34.8%) or megaconia
(26.0%). Mitochondrial respiratory chain complex 4 defects were
also detected in 12 patients, and complex 1 defects in 11 patients
(Tables 2, 3).
Mitochondrial DNA Mutations in Leigh
Syndrome
We analyzed 16,500 base pairs of mitochondrial DNA using
direct sequencing to confirm the most reliable mutations
related to Leigh syndrome based on established genetic reports.
Mutations at base pairs 10,191, 13,513, and 8,993 were revealed
in relatively larger number of patients suffering Leigh syndrome
with epilepsy (Table 4).
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TABLE 1 | Comparison of clinical characteristics in Leigh syndrome participants with and without epilepsy.
General characteristics Total (N = 25) Epilepsy (N = 14) Without Epilepsy (N = 11) P-value
Sex (male:female) 10 (40.0%):15 (60.0%) 7 (50.0%):7 (50.0%) 3 (27.3%):8 (72.7%) 0.414
Family history
Mitochondrial disease 4/25 (16.0%) 3/14 (21.4%) 1/11 (9.1%) 0.604
Other neurologic disease 3/25 (12.0%) 1/14 (7.1%) 2/11 (18.2%) 0.565
None 18/25 (72.0%) 10/14 (71.4%) 8/11 (72.7%) 0.649
Epilepsy 0/25 (0.0%) 0/14 (0.0%) 0/11 (0.0%) –
First onset symptoms
Developmental regression 10/25 (40.0%) 7/14 (50.0%) 3/11 (27.3%) 0.414
Ptosis 4/25 (16.0%) 2/14 (14.3%) 2/11 (18.2%) 0.604
Ataxia 4/25 (16.0%) 1/14 (7.1%) 3/11 (27.3%) 0.288
Respiratory difficulty 4/25 (16.0%) 1/14 (7.1%) 3/11 (27.3%) 0.288
Seizure 3/25 (12.0%) 3/14 (21.4%) 0/11 (0.0%) 0.230
Age of 1st symptoms (years) 1.44 (0.15–9.88) 1.46 (0.16–4.65) 1.26 (0.50–9.88) 0.827
Age of muscle biopsy (years) 2.02 (0.52–20.33) 1.88 (0.52–7.33) 3.90 (1.05–20.33) 0.101
Interval from 1st symptom to confirmative diagnosis of LS (months) 7.87 (0.90–136.00) 7.85 (0.90–64.17) 9.07 (1.27–136.00) 0.488
Interval for follow up (years) 5.73 (0.74–10.94) 5.9 (0.89–10.56) 4.6 (0.74–10.98) 0.477
Additional system involvement
Neuromuscular 25/25 (100.0%) 14/14 (100.0%) 11/11 (100.0%) –
Ophthalmic 15/25 (60.0%) 10/14 (71.4%) 5/11 (45.5%) 0.241
Respiratory 9/25 (36.0%) 7/14 (50.0%) 2/11 (18.2%) 0.208
Cardiologic 8/25 (32.0%) 4/14 (28.6%) 4/11 (36.4%) 0.504
Gastrointestinal 8/25 (32.0%) 7/14 (50.0%) 1/11 (9.1%) 0.042
Endocrinologic 7/25 (28.0%) 5/14 (35.7%) 2/11 (18.2%) 0.407
Renal 4/25 (16.0%) 3/14 (21.4%) 1/11 (9.1%) 0.604
Auditory 3/25 (12.0%) 3/14 (21.4%) 0/11 (0.0%) 0.230
Urologic 3/25 (12.0%) 2/14 (14.3%) 1/11 (9.1%) 0.593
Skeletal 3/25 (12.0%) 3/14 (21.4%) 0/11 (0.0%) 0.230
Neuromuscular symptoms
Developmental delay 17/25(68.0%) 9/14 (64.3%) 8/11 (72.7%) 0.496
Seizure 8/25 (32.0%) 8/14 (57.1%) 0/11 (0.0%) 0.003
Dystonia 7/25 (28.0%) 5/14 (35.7%) 2/11 (18.2%) 0.407
Ataxia 5/25 (20.0%) 2/14 (14.3%) 3/11 (27.3%) 0.623
Spasticity 5/25 (20.0%) 4/14 (28.6%) 1/11 (9.1%) 0.341
Dysarthria 3/25 (12.0%) 1/14 (7.1%) 2/11 (18.2%) 0.565
Psychomotor delay 2/25 (8.0%) 0/14 (0.0%) 2/11 (18.2%) 0.183
Muscle weakness 1/25 (4.0%) 1/14 (7.1%) 0/11 (0.0%) 0.560
Epilepsy in Leigh Syndrome
A total of 14 patients with Leigh syndrome in the present study
were confirmed to also have epilepsy (Table 5). The mean age of
seizure onset among these individuals was approximately 2 years.
During the initial stage, their seizure frequency reported was
about seven times per month. We found that six patients (42.8%)
had a focal seizure locus while 5 (35.7%) had generalized seizure
semiology. Complex partial seizure was the most common (3/14)
(21.4%) type of focal seizure observed. As for generalized seizure
types, myoclonic seizure, tonic seizure, atonic seizure, and tonic-
clinic seizure were observed with relatively even prevalence
among patients. In addition, two patients showed partial seizure
with secondary generalization and one patient had unclassified
epileptic seizures.
All patients showed slow and disorganized background neural
activity while eight exhibited epileptic discharges on EEG.
Among them, five patients had focal sharp or spike waves,
accounting for 35.7% of the total. In this study, none of the
patients with Leigh syndrome experiencing epilepsy had an
episode of status epilepticus.
A total of 12 patients (85.7%) were taking anti-epileptic drugs
at the time. Eight patients were taking only one AED (57.1%).
However, four patients failed to control their seizure within 1
year of their initial treatment and went on to taking two or
more types of AEDs. During an average follow-up period of 5.7
years, eight patients were taking one AED at the time of the last
visit, accounting for 57.1% of the total. However, the number of
patients taking three or more multiple AEDs was four (28.6%).
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TABLE 2 | Comparison of neuroimaging findings in Leigh syndrome participants with and without epilepsy.
Neuroimaging findings Total (N = 25) Epilepsy (N = 14) Without Epilepsy (N = 11) P-value
MRI ABNORMALITIES
Basal ganglia 23/25 (92.0%) 14/14 (100.0%) 9/11 (81.8%) 0.183
Brain stem 19/25 (76.0%) 12/14 (85.7%) 7/11 (63.6%) 0.350
Cerebellar atrophy 15/25 (60.0%) 9/14 (64.3%) 6/11 (54.5%) 0.697
Thalamus 12/25 (40.0%) 9/14 (64.3%) 3/11 (27.3%) 0.111
Diffuse cerebral atrophy 11/25 (44.0%) 9/14 (64.3%) 2/11 (18.2%) 0.042
Cortex 9/25 (30.0%) 8/14 (57.1%) 1/11 (9.1%) 0.033
White matter 7/25 (25.0%) 6/14 (42.9%) 1/11 (9.1%) 0.09
MR SPECTROSCOPY
Lactate peak 15/22 (68.2%) 8/13 (61.5%) 7/9 (77.8%) 0.648
MR, magnetic resonance; MRI, magnetic resonance imaging.
TABLE 3 | Comparison of diagnostic evaluation between Leigh syndrome participants with and without epilepsy.
Diagnostic evaluation Total Epilepsy (N = 14) Without epilepsy (N = 11) P-value
LACTIC ACIDOSIS (N = 25)
Within normal range 4/25 (16.0%) 1/14 (7.1%) 3/11 (27.3%) 0.288
Mildly increased (<2-fold) 20/25 (80.0%) 12/14 (85.7%) 8/11 (72.7%) 0.623
Moderated increased (2–3-fold) 1/25 (4.0%) 1/14 (7.1%) 0/11 (0.0%) 0.560
Severe increased (≥3-fold) 0/25 (0.0%) 0/14 (0.0%) 0/11 (0.0%) –
MUSCLE BIOPSY OBTAINED (N = 23)
Light microscopic changes
Specific findings for mitochondrial disease 4/23 (17.4%) 2/13 (15.4%) 2/10 (20.0%) 0.596
Non-specific findings 2/23 (8.7%) 1/13 (7.7%) 1/10 (10.0%) 0.692
Electron microscopic changes
Pleoconia 8/23 (34.8%) 4/13 (30.4%) 4/10 (40.0%) 0.685
Megaconia 6/23 (26.0%) 4/13 (30.8%) 2/10 (20.0%) 0.660
MRC enzyme assay
Complex IV defect 12/23 (52.2%) 6/13 (46.2%) 6/10 (60.0%) 0.680
Complex I defect 11/23 (47.8%) 7/13 (53.8%) 4/10 (40.0%) 0.680
MRC, mitochondrial chain complex.
Two patients were on the ketogenic diet and did not fully respond
to multiple AEDs.
After we started the AED, we summarized the treatment
effects of the patients. Six patients became seizure free and three
patients achieved decreased seizure frequency. There were two
patients with no change of seizure frequency and one patient
suffered increased seizure frequency. However, over the entire
follow-up period, seizure free status was observed in 8 out of
14 patients.
Comparison of Those With Leigh
Syndrome With and Without Comorbid
Epilepsy
We divided our participants, all of whom had Leigh syndrome,
into two groups based on their epilepsy status groups and
presence of mtDNA mutations. We found no statistically
significant differences in the clinical characteristics of the
two groups, except for their gastrointestinal system symptoms
and seizure history (Table 1). The presence of gastrointestinal
symptoms was significantly higher in the epilepsy group (50.0 vs.
9.1%, P = 0.042).
A comparison of MRI findings between the two groups
revealed that diffuse cerebral atrophy was significantly increased
with epilepsy (64.3 vs. 18.2%, P = 0.042). Cortex signal
abnormalities with epilepsy were also increased (57.1 vs. 9.1%,
P = 0.033). Abnormal signals in other areas on MRI and lactate
peaks on MR spectroscopy did not differ between the epilepsy
and non-epilepsy groups. Additionally, there were no statistically
significant differences in lactic acidosis, muscle biopsy findings,
mitochondrial chain complex defects, or mitochondrial DNA
mutation types between the two groups.
DISCUSSION
Epilepsy is one of the most significant clinical manifestations of
mitochondrial disorders. Mitochondrial chain impairments are
often caused by neuronal mitochondrial DNA damage, which
is an aspect of epileptogenesis (11). The incidence of epilepsy
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TABLE 4 | Comparison of mtDNA mutations between Leigh syndrome participants with and without epilepsy.
mtDNA mutations Total (N = 25) Epilepsy (N = 14) Without epilepsy (N = 11) P-value
10191 T>C 4/25 (16.0%) 4/14 (28.6%) 0/11 (0.0%) 0.105
13513 G>A 4/25 (16.0%) 1/14 (7.1%) 3/11 (27.3%) 0.288
8993 T>G 4/25 (16.0%) 2/14 (14.3%) 2/11 (18.2%) 0.604
8993 T>C 3/25 (12.0%) 1/14 (7.1%) 2/11 (18.2%) 0.565
9176 T>C 3/25 (12.0%) 1/14 (7.1%) 2/11 (18.2%) 0.565
3697 G>A 2/25 (8.0%) 1/14 (7.1%) 1/11 (9.1%) 0.697
10158 T>C 1/25 (4.0%) 1/14 (7.1%) 0/11 (0.0%) 0.560
10744 A>G 1/25 (4.0%) 1/14 (7.1%) 0/11 (0.0%) 0.560
11777 C>A 1/25 (4.0%) 1/14 (7.1%) 0/11 (0.0%) 0.560
14459 G>A 1/25 (4.0%) 0/14 (0.0%) 1/11 (9.1%) 0.440
9185 T>C 1/25 (4.0%) 0/14 (0.0%) 1/11 (9.1%) 0.440
in mitochondrial encephalopathy presents ranges widely, though
most studies report 35–61% (11–13). In our study, 14 out of
25 patients had epilepsy, which corresponds to a morbidity of
56%. This was within the range of the existing reference but
on the higher side. The prevalence of epilepsy in individuals
with Leigh syndrome ranges sporadically, but is generally high,
similar to that of mitochondrial disorder in individuals with
epilepsy (3, 5, 14). Other mitochondrial disorders accompanying
epilepsy, such as Mitochondrial encephalopathy, lactic acidosis,
and stroke-like episodes (MELAS) and Myoclonic epilepsy with
ragged red fibers (MERRF), were reported by Lee et al. to have
a similarly high prevalence (4, 15). Despite this, seizure is not
included as a diagnostic feature of Leigh syndrome. However,
epilepsies in individuals with Leigh syndrome are often noted to
be relatively high, possibly due to the confusion of seizures with
other neuromuscular symptoms such as dystonia or spasticity.
The present study indicates that the incidence of epilepsy in Leigh
syndrome patients falls within previously established ranges.
Given this, we conclude that the incidence of epilepsy may differ
from that of subtypes of mitochondrial disorders, as there is
cortical dysfunction in each which may limit the accuracy of a
purely syndromic diagnosis.
Cortical abnormalities revealed via neuroimaging (e.g.,
MRI) are often used to indicate epilepsy (16, 17). Similarly,
ubiquinone deficiencies, MELAS, POLG (polymerase subunit
gamma) mutation, and Kearns-Sayre Syndrome are all associated
with various lesions and brain MRI abnormalities, including
alterations in the cerebral cortex, seizure, or stroke-like episodes
(18). However, most Leigh patients also exhibit abnormalities in
the brain stem or basal ganglia, with rare cases exhibiting cortical
lesion on MRI (19, 20). In the present study, the proportion
of patients with Leigh syndrome revealed to have some cortical
abnormalities on MRI was over half, especially in those with
epilepsy, indicating that cortical changes on neuroimaging may
reflect impending epilepsy in Leigh syndrome. Mitochondrial
disorders often feature critical dysfunctions in the CNS, which
stem from the high-energy demands of the CNS, resulting
in diffuse or focal brain tissue atrophy (9, 21). The present
study reveals a relatively high proportion of cerebral atrophy
among those with Leigh syndrome and significantly increased
rates in those with epilepsy. It is possible that epilepsy’s
high metabolic cost may lead to accelerated central nervous
dysfunction with mitochondrial dysfunction, ultimately leading
to the deterioration that occurs in the natural course of Leigh
syndrome with comorbid epilepsy. Sofou et al. found that
multiple factors, including epilepsy and birth defects, resulted
in exacerbated Leigh syndrome. Typically, patients with Leigh
syndrome are thought to live 2 or 3 years beyond first symptom
onset, with those with late onset Leigh syndrome living up to 20
years of age. However, in most patients, deterioration begins to
accelerate at ∼20 months of age (22, 23). In patients with Leigh
syndrome with comorbid epilepsy, timely evaluation including
neuroimaging is particularly critical, as their symptoms may
worsen and have deteriorating prognosis. Based on the results
that diffuse atrophy is more associated with Leigh syndrome
with epilepsy, it can serve as a good imaging indicator of
disease progression. So, we strongly suggest that neuroimaging
may provide critical clues about the disease course and may
be helpful for the detection of epilepsies among patients with
Leigh syndrome.
Mitochondrial dysfunction leads to various, non-specific
clinical phenotypes including gastrointestinal symptoms such
as dysphagia, malnutrition, gastroparesis, and constipation
(8). Gastrointestinal dysmotility may be caused by decreased
mitochondrial proliferation and thus leads to marked atrophy of
the external layer of the muscular propria (24). Some studies of
mitochondrial neuro-gastro-intestinal encephalopathy (MNGIE)
have also reported its association with non-specific neurologic
symptoms, such as ophthalmoplegia and ptosis 9 (25, 26). In their
analysis of patients with MELAS, de Laat et al. found that 20%
experienced dysphagia and constipation while 40% experienced
gastroparesis, which often contributes to nutrition absorption
failures and malnutrition (27). Gastrointestinal symptoms may
be due to either central or peripheral neuropathy, though
epilepsies such as panayiotopoulos epilepsy or the aura that
accompanies a focal epilepsy are often misdiagnosed as celiac
disease or other gastrointestinal diseases (28) and thus the
connection between these symptoms and epilepsies remains
poorly understood. For instance, Yeh et al. reported a high risk of
gastrointestinal hemorrhage in epilepsy patients (29), though this
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TABLE 5 | Characteristics of epilepsy in Leigh syndrome patients (total N = 14).
Age of first seizure (years) 2.10 (0.12–4.92)*
Initial seizure frequency/month 7.14 (1–24)*
SEIZURE TYPE
Focal seizures 6/14 (42.8%)
Simple partial without motor signs 1/14 (7.1%)
Simple partial with motor signs 2/14 (14.3%)
Complex partial 3/14 (21.4%)
Generalized seizures 5/14 (35.7%)
Myoclonic seizures 2/14 (14.3%)
Tonic seizures 1/14 (7.1%)
Atonic seizures 1/14 (7.1%)
Tonic-clonic seizures 1/14 (7.1%)
Partial seizure with secondary generalization 2/14 (14.3%)
Unclassified epileptic seizures 1/14 (7.1%)
Mixed type of seizures 4/14(28.6%)
ELECTROENCEPHALOGRAPHY
Background rhythm
Slow and disorganized 14/14 (100.0%)
Asymmetric focal slowing 6/14 (42.8%)
Epileptiform discharges
No epileptic discharges 6/14 (42.8%)
Focal sharp/spike waves 5/14 (35.7%)
Multifocal sharp/spike waves 1/14 (7.1%)
Generalized sharp and waves 2/14 (14.3%)
Generalized paroxysmal fast activities 2/14 (14.3%)
Electrographic seizure
Generalized seizure 1/14 (7.1%)
Focal seizure 2/14 (14.3%)
Numbers of status epilepticus 0/14 (0.0%)
TREATMENT OPTIONS
With antiepileptic drugs (AEDs) 12/14 (85.7%)
Levetiracetam 4/14 (28.6%)
Lamotrigine 3/14 (21.4%)
Oxecarbamazepine 3/14 (21.4%)
Zonisamide 3/14 (21.4%)
Topiramate 2/14 (14.3%)
Phenytoin 1/14 (7.1%)
Carbamazepine 1/14 (7.1%)
Numbers of initial treatment 0.7 (0–3.0)*
No AED 2/14 (14.3%)
1 AED 8/14 (57.1%)
2 AEDs 3/14 (21.4%)
3 AEDs 1/14 (7.1%)
Numbers of last visit 1.6 (0–5.0) *
No AED 2/14 (14.3%)
1 AED 6/14 (42.9%)
2 AEDs 2/14 (14.3%)
3 AEDs 2/14 (14.3%)
>3 AEDs 2/14 (14.3%)
Ketogenic diet 2/14 (14.3%)
RESPONSE TO AEDs AFTER 1 YEAR
Seizure free 6/14 (42.8%)
Decreased seizure frequency 3/14 (21.4%)
(Continued)
TABLE 5 | Continued
>90% reduction of seizures frequency 1/14 (7.1%)
50–90% reduction of seizures frequency 1/14 (7.1%)
<50% reduction of seizures frequency 1/14 (7.1%)
No change of seizure frequency 2/14 (14.3%)
Increased seizure frequency 1/14 (7.1%)
Seizure free at last visit 8/14 (57.1%)
*Marked the median with interquartile range.
was not correlated with the severity of the epilepsy or considered
to be a risk factor for future seizures. Similarly, in the present
study, we found a relatively high proportion of gastrointestinal
symptoms among patients with Leigh syndrome. This incidence
of gastrointestinal symptoms was significantly increased among
those with epilepsy. Gastrointestinal dysfunctions in patients
with Leigh syndrome may be caused by malabsorption
or malnutrition, which can lead to epileptogenesis (30).
Malnutrition also exacerbates immunodeficiencies and increases
infection risk via blunting cell-mediated immunity, phagocytosis,
and complementary system activity, which collectively also
increase risk for epilepsy. Additionally, malabsorption can
result in micronutrient deficiencies of calcium, magnesium,
sodium, and other vital molecules, altering neuronal excitability
and epileptic activity (31). The present study indicates that
gastrointestinal dysmotility in individuals with Leigh syndrome
may induce malabsorption and malnutrition, which can facilitate
epileptic activity.
Others have also reported a correlation between epilepsy
and mitochondrial disease. For instance, Khurana et al. found
that focal seizures, with or without secondary generalization,
were common among those with mitochondrial disorders (12).
Canafoglia et al. reported that patients with Leigh syndrome often
experienced focal seizures more than they did generalized ones
(4). Similarly, the present study finds an elevated proportion
of focal seizure history among those with Leigh syndrome
and epilepsy. Others have reported conflicting results. For
instance, Lee et al. found that, of 48 patients with mitochondrial
dysfunction, focal seizures were evident in 8 (16.7%), while
generalized seizures were evident in 14 patients (29.2%) (13).
While some results have differed from ours, the present study
included various types of mitochondrial disorders, allowing
for more precise resolution of participants symptomatology.
Other reports of mitochondrial disorders have found slow and
disorganized background rhythms with focal epileptic discharges
on EEG, with over half of mitochondrial dysfunction patients
exhibiting focal or multifocal spike waves and a high proportion
of focal or multifocal sharp waves in patients with Leigh
syndrome (4, 12). All patients assessed here exhibited slow
and disorganized background EEG signs, results which agree
with those reported previously. Some participants in the present
study, however, presented multifocal spike wave discharges on
EEG. As we have found here, Finsterer et al. also found that
various subtypes of mitochondrial disorder are associated with
different types of epilepsy (32). For instance, MERRF presents
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with generalized epilepsy and EEG spikes while MELAS presents
with focal or generalized seizures and focal or multifocal EEG
spikes (15, 33). Mitochondrial disorder patients assessed in the
present study exhibited slow and disorganized background EEG
signals, though they also exhibited multifocal or focal spikes
depending on the mitochondrial disorder subtype. Other aspects
of epilepsy also differ between mitochondrial disease cases. For
instance, Lee et al. compared reductions in seizure frequency
with more than 1 year of anti-epileptic treatment and found that
13% of syndromic mitochondrial disease patients experienced
50–75% decreases while 26% of nonsyndromic mitochondrial
patients experienced decreases of<25% (34). By comparison, the
results of the present study reveal that 42.8% of Leigh syndrome
patients were seizure free after 1 year and that 57.1% of patients
were seizure free upon their last clinic visit. These results indicate
that prevalence of seizure semiology on EEG and the effects of
anti-epileptic treatment may differ depending on the particular
subtype of mitochondrial disorder (35).
While our data reveal some interesting trends with regard
to Leigh syndrome with mtDNA mutations, the study’s sample
size was not large enough to parse particular subtype differences,
posing a significant limitation to the present study. In this study,
we investigated the association regarding epilepsy in patients
with mtDNA associated Leigh syndrome only. Nevertheless,
a study of epilepsy in Leigh syndrome with nuclear DNA
(nDNA) mutations is further needed. A comparative study of the
epilepsy pattern between Leigh syndrome with mtDNAmutation
and with nDNA mutation would be worthwhile for the better
understanding of Leigh syndrome.
CONCLUSION
Epilepsy is a significant neurologic manifestation of Leigh
syndrome. In the present study, we found an increase in the
prevalence of gastrointestinal symptoms among those with Leigh
syndrome and epilepsy (vs. without epilepsy), potentially due
to the high energy demands associated with epilepsy. We also
found that acute imaging changes may indicate an increased
risk for epilepsy in individuals with Leigh syndrome, suggesting
that imaging should be conducted within 2 years of diagnosis to
determine the syndrome’s natural course. Additionally, various
types of epilepsy and differences in seizure semiology on
EEG findings were also found to be associated with different
mitochondrial disorders. The optimal and precise diagnosis of
these disorders may lead to the increased accuracy of their
diagnosis and improved treatments for epilepsy in mitochondrial
disorders. Further studies that include the various subtypes
of mitochondrial disorders and the use of larger samples are
needed to develop improved diagnosis and treatment strategies.
Given our findings, we contend that specialists in mitochondrial
disorders should create individualized treatment plans and assess
the disorder’s natural course and prognosis in each case that they
treat. As the science on these disorders moves forward, so too will
its treatment.
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